Synterex, Inc. -

In Part 2 of our AI & Automation series, we delve deeper into practical case studies and real-world applications of AI in medical communications. Join Synterex as we explore the next phase of AI adoption, focusing on automating business processes, optimizing medical writing workflows, and leveraging AI for better stakeholder engagement.

Watch now to learn:
How to build a business information library for efficient content generation
The role of AI-driven automation in medical writing and regulatory documentation
Best practices for explaining AI adoption to stakeholders and clients
Examples of using automation to streamline business processes

Synterex, Inc. -

Synterex partnered with MarketBeam to host "Automation & AI to Solve Business Problems in Medical Communications" in June 2024.

Discover how AI and automation are transforming medical communications in this insightful webinar hosted by Synterex. From balancing regulatory risks to optimizing business practices, this webinar delves into the practical applications of AI across the medical writing landscape.

Watch now to learn:
How AI and automation can streamline medical writing processes
Best practices for AI compliance and governance
Real-world case studies on AI’s impact on business efficiency
Key insights into managing AI-driven risks in clinical and regulatory documentation

Synterex, Inc. -

Prior to the FD&C Act, pharmaceutical companies were not required to provide proof of drug safety or a disclosure of all active ingredients. Since then, all new drugs undergo an intensive review process by the Food and Drug Administration (FDA), and ever-evolving guidance and regulations ensure that both new drugs and those with updated characteristics, such as dosing, delivery, and expanded indications, are safe and effective for the intended populations. A gap remains, however, for drug investigations including and targeted for children of varying ages.

Download and read now for more insights!

Synterex, Inc. -

Innovative development of human drugs, biologics, and medical devices (medical products) and their quick advancement through the United States Food and Drug Administration (FDA) approval pipeline is necessary to improve the lives of patients. It is also imperative for sponsors to consider diversity when enrolling study participants throughout the clinical development pipeline to adequately represent the population of patients who have a disease or condition.

Download and read now for more insights!

G&L Healthcare Advisors -

Bill Griffiths, Chief Regulatory Affairs Officer, examines the impact of G&L's recent acquisition of SmartStep Consulting.

G&L Healthcare Advisors -

Read how our expertise in Quality Assurance assisted our clients on their compliance journies. 

G&L Healthcare Advisors -

Our experts are ready to help you make your budgets go further.At G&L, we understand that companies are facing increasing pressure to "do more with less" due to budget constraints.

A key part of our services includes business advisory, transformation, process excellence, and people strategy, with a focus on identifying cost efficiencies for the life sciences sector, particularly in regulatory affairs. 

To support our clients, we provide financial reassurance through our cost-effective Centres of Excellence located in the UK, Ireland, and India.

Berry Consultants -

This white paper will explore the business benefits and case of using the FACTS simulation software for all your clinical trial designs.

Insife -

Mark your calendars for September 26th and join us at the Novartis Campus in Basel for the Insife Annual Convention - your calendars for September 26th and join us at the Novartis Campus in Basel for the Insife Annual Convention - Connect. Collaborate. Community.ect. Collaborate. Community.Mark your calendars for September 26th and join us at the Novartis Campus in Basel for the Insife Annual Convention - Connect. Collaborate. Community.

Cencora -

Patient assistance programs face constraints on the path to access. But new digital solutions are emerging that can help. They enhance the performance of these programs at every step. See the ways they streamline operations for faster and more effective treatment delivery. 

Cencora -

A customized channel strategy aims to create optimal product access based on product attributes and patient needs. Whether a new biopharma company is preparing for its first launch or an established one is launching in a different therapeutic area, distribution channel strategy decisions can help successfully navigate the complexity and accelerate time to market.

Cencora -

Engaging with healthcare decision makers (HCDMs) is paramount to success. Brand visibility, information sharing, and insights from the HCDM community is vital. Discover how two biopharma companies, with diverse product portfolios maximized their outreach strategies through enterprise subscriptions to FormularyDecisions.

Cencora -

Health care is at an inflection point in the US and Europe, marked by the introduction of new policies aimed at maintaining the sustainability of healthcare systems whilst balancing innovation and ensuring patient access to essential medications. But what are the implications of these policies for stakeholders? How can these stakeholders forge ahead and navigate this evolving landscape?